Cargando…

Study on Tim3 Regulation of Multiple Myeloma Cell Proliferation via NF-κB Signal Pathways

OBJECTIVE: As an important negative regulatory factor of immunological cells, Tim3 plays a regulating role in tumor immune microenvironment. The purpose of this study was to investigate the expression of Tim3 on MM cells and its effect on the proliferation and apoptosis of MM cells, as well as its p...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Zhaoyun, Xiang, Chenhuan, Han, Mei, Meng, Nanhao, Luo, Jingyi, Fu, Rong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7710973/
https://www.ncbi.nlm.nih.gov/pubmed/33330064
http://dx.doi.org/10.3389/fonc.2020.584530
_version_ 1783618045583818752
author Liu, Zhaoyun
Xiang, Chenhuan
Han, Mei
Meng, Nanhao
Luo, Jingyi
Fu, Rong
author_facet Liu, Zhaoyun
Xiang, Chenhuan
Han, Mei
Meng, Nanhao
Luo, Jingyi
Fu, Rong
author_sort Liu, Zhaoyun
collection PubMed
description OBJECTIVE: As an important negative regulatory factor of immunological cells, Tim3 plays a regulating role in tumor immune microenvironment. The purpose of this study was to investigate the expression of Tim3 on MM cells and its effect on the proliferation and apoptosis of MM cells, as well as its potential mechanism. METHODS: In this study, the expression of Tim3 was detected on myeloma cells (CD38(+)CD138(+) cells) of bone marrow by flow cytometry (FCM) from 167 patients with MM and 51 healthy donors as controls and making correlation analysis with related clinical indexes. In vitro, MM cell lines (RPMI-8226 and U266) were treated with Tim3 knock-down alone, bortezomib alone and combination of Tim3 knock-down and bortezomib, then cell proliferation, cell apoptosis and downstream signaling pathway were detected by CCK-8, FCM, RT-PCR and western blot. RESULTS: The expression of Tim3 on myeloma cells in MM patients was significantly higher than normal control group and positively correlated with β(2) microglobulin, creatine, and plasma cells of bone marrow, negatively correlated with hemoglobin and red blood cells. In vitro, we validated the high expression of Tim3 in RPMI-8226 and U266 cell lines. After Tim3 knock-down, the cell proliferation was inhibited and cell apoptosis was induced, the relative mRNA and protein expression of Tim3 and NF-κB signal pathway (PI3K, AKT, mTOR, NF-κB) were significantly decreased. Also, the cell proliferation was inhibited, cell apoptosis was increased, the relative mRNA and protein expression of NF-κB were decreased significantly in combination group than bortezomib or Tim3 knock-down group. CONCLUSIONS: The high expression of Tim3 on MM cells is associated with progression of MM patients. Tim3 maybe regulate the proliferation of MM cells via NF-κB signal pathway. Down-regulation of Tim3 expression can inhibit proliferation and induce apoptosis of MM cells, also has an additive inhibitory effect of bortezomib on NF-κB signaling pathway, then inhibit proliferation and induce apoptosis. Therefore, Tim3 may be a potential target for the treatment of MM.
format Online
Article
Text
id pubmed-7710973
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-77109732020-12-15 Study on Tim3 Regulation of Multiple Myeloma Cell Proliferation via NF-κB Signal Pathways Liu, Zhaoyun Xiang, Chenhuan Han, Mei Meng, Nanhao Luo, Jingyi Fu, Rong Front Oncol Oncology OBJECTIVE: As an important negative regulatory factor of immunological cells, Tim3 plays a regulating role in tumor immune microenvironment. The purpose of this study was to investigate the expression of Tim3 on MM cells and its effect on the proliferation and apoptosis of MM cells, as well as its potential mechanism. METHODS: In this study, the expression of Tim3 was detected on myeloma cells (CD38(+)CD138(+) cells) of bone marrow by flow cytometry (FCM) from 167 patients with MM and 51 healthy donors as controls and making correlation analysis with related clinical indexes. In vitro, MM cell lines (RPMI-8226 and U266) were treated with Tim3 knock-down alone, bortezomib alone and combination of Tim3 knock-down and bortezomib, then cell proliferation, cell apoptosis and downstream signaling pathway were detected by CCK-8, FCM, RT-PCR and western blot. RESULTS: The expression of Tim3 on myeloma cells in MM patients was significantly higher than normal control group and positively correlated with β(2) microglobulin, creatine, and plasma cells of bone marrow, negatively correlated with hemoglobin and red blood cells. In vitro, we validated the high expression of Tim3 in RPMI-8226 and U266 cell lines. After Tim3 knock-down, the cell proliferation was inhibited and cell apoptosis was induced, the relative mRNA and protein expression of Tim3 and NF-κB signal pathway (PI3K, AKT, mTOR, NF-κB) were significantly decreased. Also, the cell proliferation was inhibited, cell apoptosis was increased, the relative mRNA and protein expression of NF-κB were decreased significantly in combination group than bortezomib or Tim3 knock-down group. CONCLUSIONS: The high expression of Tim3 on MM cells is associated with progression of MM patients. Tim3 maybe regulate the proliferation of MM cells via NF-κB signal pathway. Down-regulation of Tim3 expression can inhibit proliferation and induce apoptosis of MM cells, also has an additive inhibitory effect of bortezomib on NF-κB signaling pathway, then inhibit proliferation and induce apoptosis. Therefore, Tim3 may be a potential target for the treatment of MM. Frontiers Media S.A. 2020-11-19 /pmc/articles/PMC7710973/ /pubmed/33330064 http://dx.doi.org/10.3389/fonc.2020.584530 Text en Copyright © 2020 Liu, Xiang, Han, Meng, Luo and Fu http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Oncology
Liu, Zhaoyun
Xiang, Chenhuan
Han, Mei
Meng, Nanhao
Luo, Jingyi
Fu, Rong
Study on Tim3 Regulation of Multiple Myeloma Cell Proliferation via NF-κB Signal Pathways
title Study on Tim3 Regulation of Multiple Myeloma Cell Proliferation via NF-κB Signal Pathways
title_full Study on Tim3 Regulation of Multiple Myeloma Cell Proliferation via NF-κB Signal Pathways
title_fullStr Study on Tim3 Regulation of Multiple Myeloma Cell Proliferation via NF-κB Signal Pathways
title_full_unstemmed Study on Tim3 Regulation of Multiple Myeloma Cell Proliferation via NF-κB Signal Pathways
title_short Study on Tim3 Regulation of Multiple Myeloma Cell Proliferation via NF-κB Signal Pathways
title_sort study on tim3 regulation of multiple myeloma cell proliferation via nf-κb signal pathways
topic Oncology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7710973/
https://www.ncbi.nlm.nih.gov/pubmed/33330064
http://dx.doi.org/10.3389/fonc.2020.584530
work_keys_str_mv AT liuzhaoyun studyontim3regulationofmultiplemyelomacellproliferationvianfkbsignalpathways
AT xiangchenhuan studyontim3regulationofmultiplemyelomacellproliferationvianfkbsignalpathways
AT hanmei studyontim3regulationofmultiplemyelomacellproliferationvianfkbsignalpathways
AT mengnanhao studyontim3regulationofmultiplemyelomacellproliferationvianfkbsignalpathways
AT luojingyi studyontim3regulationofmultiplemyelomacellproliferationvianfkbsignalpathways
AT furong studyontim3regulationofmultiplemyelomacellproliferationvianfkbsignalpathways